Ambu (AMBU-B.CO) Stock Analysis & AI Equity Report
Ambu (AMBU-B.CO) overview
Ambu (AMBU-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, Ambu reported revenue of DKK 6,037m and operating profit of DKK 784m; the year-end share price was 92.60 DKK and market capitalisation was DKK 24,676m. Ambu is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ambu's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Ambu
Ambu A/S is a Danish medical device company focused on single-use endoscopy, anesthesia, and patient monitoring products. Its portfolio includes bronchoscopes, gastroscopes, video laryngoscopes, ventilation equipment, and ECG, EMG and EEG electrodes. The company develops, manufactures, and sells these devices to hospitals and healthcare professionals worldwide.
Generate the Ambu report
Ambu is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ambu and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.